DNA inhibitors for the treatment of brain tumors

Lucia Lisi, Marta Chiavari, Gabriella Maria Pia Ciotti, Pedro M. Lacal, Pierluigi Navarra, Grazia Graziani

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

2 Citazioni (Scopus)


Introduction: The worldwide incidence of central nervous system (CNS) primary tumors is increasing. Most of the chemotherapeutic agents used for treating these cancer types induce DNA damage, and their activity is affected by the functional status of repair systems involved in the detection or correction of DNA lesions. Unfortunately, treatment of malignant high-grade tumors is still an unmet medical need. Areas covered: We summarize the action mechanisms of the main DNA inhibitors used for the treatment of brain tumors. In addition, studies on new agents or drug combinations investigated for this indication are reviewed, focusing our attention on clinical trials that in the last 3 years have been completed, terminated or are still recruiting patients. Expert opinion: Much still needs to be done to render aggressive CNS tumors curable or at least to transform them from lethal to chronic diseases, as it is possible for other cancer types. Drugs with improved penetration in the CNS, toxicity profile, and activity against primary and recurrent tumors are eagerly needed. Targeted agents with innovative mechanisms of action and ability to harness the cells of the tumor microenvironment against cancer cells represent a promising approach for improving the clinical outcome of CNS tumors.
Lingua originaleEnglish
pagine (da-a)1-13-13
Stato di pubblicazionePubblicato - 2020


  • DNA damage
  • DNA inhibitors
  • Glioblastoma
  • anti-VEGF therapy
  • brain tumors
  • chemotherapy
  • clinical trials
  • immune checkpoint inhibitors
  • monoclonal antibodies
  • temozolomide


Entra nei temi di ricerca di 'DNA inhibitors for the treatment of brain tumors'. Insieme formano una fingerprint unica.

Cita questo